ORCHPHARMANSEOrchid Pharma LimitedHighNeutral
Announced Thu, 26 Jun · 17:34 IST

Orchid Pharma Limited has informed the Exchange about Shareholders meeting

Nclt Scheme FiledStrategic Transactions View source PDF

ORCHPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Orchid Pharma held an NCLT-convened meeting of its equity shareholders on June 26, 2025, to consider and approve the Scheme of Amalgamation and Arrangement with Dhanuka Laboratories Limited (the Amalgamating Company). The meeting was initially adjourned for 30 minutes due to lack of quorum, then resumed via video conferencing with Mr. R. Varadharajan (NCLT-appointed Chairperson) presiding. Remote e-voting ran from June 23 to June 25, 2025, with an additional 30-minute voting window after the meeting concluded. The Managing Director briefed shareholders on the merger scheme. Voting results by the Scrutinizer (Ms. Vinitha Varshini K) are awaited and will be shared with NSE, BSE, and posted on the company's and NSDL websites within prescribed timelines.

Likely market impact

This is a procedural step in the NCLT approval process for the Dhanuka–Orchid Pharma merger. Shareholders should watch for the e-voting results, which will indicate whether the amalgamation has secured the required shareholder approval to proceed to the next stage.